Fresenius Ends Deal to Buy Akorn, Which Pledges a Fight
Fresenius SE on Sunday said it is terminating its $4.3 billion agreement to buy generic-drug maker Akorn Inc., but Akorn said it intends to see the deal go through.
from Biotech News
Fresenius SE on Sunday said it is terminating its $4.3 billion agreement to buy generic-drug maker Akorn Inc., but Akorn said it intends to see the deal go through.
The most important thing is to improve and not stop. Even if you have taken some course, this does not mean that you are now a guru. You need to constantly practice, learn something new.
0 Comments